Stay updated with breaking news from Functional Decline. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Doctors at University of Washington treated their first patient with lecanemab -- a new early Alzheimer's drug shown to slow the brain's cognitive decline, researchers announced.
New anti-amyloid monoclonal antibody drugs for Alzheimer disease have produced encouraging results in targeting the accumulation of amyloid beta plaques; however, questions remain regarding the risk-benefit profile and cost implications.
Study examined the safety and efficacy of the study drug donanemab in participants with early Alzheimer's disease (AD).
Almost half of those on donanemab had no clinical progression of disease at one year compared to 29% on placebo, a study showed.
Get Cognitive decline latest news, Article video and Photos on Cognitive decline Explore latest health updates, news, information from TheHealthSite.com